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SHORT REPORT Open Access
Anti-lysophosphatidic acid antibodies improve
traumatic brain injury outcomes
Peter J Crack1*, Moses Zhang1, Maria Cristina Morganti-Kossmann2,3, Andrew J Morris4, Jonathan M Wojciak5,
Jonathan K Fleming5, Ila Karve1, David Wright6,7, Maithili Sashindranath8, Yona Goldshmit9,10, Alison Conquest9,11,
Maria Daglas8, Leigh A Johnston6,12, Robert L Medcalf8, Roger A Sabbadini5 and Alice Pébay9*
Abstract
Background: Lysophosphatidic acid (LPA) is a bioactive phospholipid with a potentially causative role in
neurotrauma. Blocking LPA signaling with the LPA-directed monoclonal antibody B3/Lpathomab is neuroprotective
in the mouse spinal cord following injury.
Findings: Here we investigated the use of this agent in treatment of secondary brain damage consequent to
traumatic brain injury (TBI). LPA was elevated in cerebrospinal fluid (CSF) of patients with TBI compared to controls.
LPA levels were also elevated in a mouse controlled cortical impact (CCI) model of TBI and B3 significantly reduced
lesion volume by both histological and MRI assessments. Diminished tissue damage coincided with lower brain IL-6
levels and improvement in functional outcomes.
Conclusions: This study presents a novel therapeutic approach for the treatment of TBI by blocking extracellular
LPA signaling to minimize secondary brain damage and neurological dysfunction.
Keywords: Lysophosphatidic acid, Traumatic brain injury, Human cerebrospinal fluid, Control cortical impact,
Magnetic resonance imaging, Anti-LPA antibody, IL-6
Findings
Traumatic brain injury (TBI) is a major cause of brain
neurotrauma, resulting in over 1.7 million brain injuries
annually in the United States. TBI commonly results
from motor vehicle accidents, falls, sports injuries or ex-
plosions, all of which disrupt normal brain function. The
primary injury can be focal or diffuse and initially pro-
duces hemorrhage and axonal injury followed by sec-
ondary effects such as edema and ischemia arising from
the activation of biochemical pathways including inflam-
mation, cell death and gliosis [1]. These secondary-phase
effects begin immediately to widen the area of injury
and can persist for weeks to months, leading to pro-
found behavioral deficits. Aggravated secondary brain
damage is also thought to impair the ability of resident
neuronal stem cells to regenerate the lost neurons.
There are no FDA-approved drugs specific for TBI treat-
ment and medical intervention is limited to supportive
care. Thus, the ideal therapy for TBI would have the
combined effects of reducing the initial injury as well as
limiting the secondary inflammatory responses while
simultaneously promoting regeneration and replacement
of lost neural tissue.
Lysophosphatidic acid (LPA) is a bioactive, pro-
inflammatory lysophospholipid found in the extracellu-
lar compartment, such as in blood and cerebrospinal
fluid (CSF). LPA mainly acts through binding to its spe-
cific G-protein-coupled receptors LPA1–7 to induce
pleiotropic effects on multiple cell types [2]. LPA is an
inflammatory mediator, released by activated platelets,
astrocytes and other pro-inflammatory cells. In the ner-
vous system, although the role of LPA signaling in de-
velopment has been described in detail, recent data also
suggest an involvement of LPA in neurotrauma [2].
This is corroborated by compelling evidence from our
group showing upregulation of LPA receptors following
* Correspondence: pcrack@unimelb.edu.au; apebay@unimelb.edu.au
1Department of Pharmacology, the University of Melbourne, Parkville,
Australia
9Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital &
Department of Ophthalmology, the University of Melbourne, East Melbourne,
Australia
Full list of author information is available at the end of the article
JOURNAL OF 
NEUROINFLAMMATION
© 2014 Crack et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Crack et al. Journal of Neuroinflammation 2014, 11:37
http://www.jneuroinflammation.com/content/11/1/37
central nervous system (CNS) neurotrauma [3,4]. Using
post-mortem human brains of normal individuals and
patients who died following acute closed-head injury,
we demonstrated that low constitutive expression levels
of LPA receptors detected in normal human brain were
upregulated following TBI. Interestingly, the upregu-
lated expression of LPA1 co-localized with astrocytes
while LPA2 was upregulated on the ependymal cell
layer of the lateral ventricles [3]. Furthermore, using a
mouse hemi-section model of spinal cord injury (SCI),
we recently demonstrated that LPA is causally involved
in the outcome of injury in that blocking its signaling
via treatment with the specific anti-LPA monoclonal
antibody (mAb), B3, limited glial scar formation, im-
proved neuronal survival, promoted neurite sprouting
and improved motor function [5]. We also observed
that injection of LPA in vivo stimulated the inflamma-
tory response and proliferation of glial cells in the Zebra-
fish following SCI [5]. In vitro studies also demonstrated
the ability of the anti-LPA mAb to block receptor signal-
ing in cells over-expressing LPA1–3 receptors [5].
Here, we report for the first time that LPA levels in-
crease significantly in CSF samples taken from TBI pa-
tients as well as from mice subjected to control cortical
impact (CCI) injury. Moreover, blocking LPA with the
specific murine anti-LPA mAb, B3, improved neuro-
logical outcomes in the CCI mice. This study provides
the first evidence that therapeutic anti-LPA mAbs could
be useful in treating TBI-associated secondary damage.
Methods
Ethics
All experimental work performed in this study was ap-
proved by the Human or Animal Research Ethics com-
mittees of the University of Melbourne (HREC1136323,
AEC0911437) or the Alfred Hospital (HREC194/05), in
accordance with the requirements of the NHMRC.
Animals
Eight-week-old male C57BL/6 J mice (23 ± 3 g) were
intravenously administered, in a blinded fashion, a single
dose of either murine IgG2β mAb targeted to LPA (B3,
25 mg/kg) [5] or an IgG2β isotype-matched mAb
(25 mg/kg) either 1 h prior to, or 30 minutes post TBI.
Injured mice were compared with uninjured sham con-
trols. At all times, the investigator was blinded to the na-
ture of the drugs to be delivered. Decoding of the
samples was only performed once data were quantified.
CSF measurement
Human CSF was obtained from patients with TBI admit-
ted to the Alfred hospital with delayed informed consent
obtained from the next of kin (Table 1). The inclusion
criteria for the patients required that they had severe
TBI with a post-resuscitation Glasgow Coma Scale
(GCS) ≤8 (except one patient with GCS = 10) who rap-
idly deteriorated, requiring an extraventricular drain de-
vice (EVD) to monitor intracranial pressure (ICP) and
therapeutic drainage of CSF [6]. Patient management in-
cluded computed tomography (CT) scans within 4 h
from TBI, followed by surgical implantation of an EVD.
CSF was drained when the ICP exceeded 20 mmHg, and
was collected daily beginning from the day of admission
(day 0) up to day 5 after injury. Exclusion criteria were
Table 1 Demographic information for patients with
severe traumatic brain injury
Patient Age Sex Oxygen saturation Injury* GCS ISS GOSE
1 23 M Normoxic 4 7 33 4
2 19 M Normoxic 1 8 30 5
3 50 M Hypoxic 1 5 41 4
4 33 M Normoxic 4 4 38 1
5 40 M Normoxic 6 7 21 6
6 33 M Hypoxic 2 3 43 4
7 21 F Normoxic 1 7 21 3
8 26 F Hypoxic 6 3 45 3
9 22 M Normoxic 5 7 30 5
10 35 M Hypoxic 6 4 45 5
11 25 M Hypoxic 1 4 41 N.A.
12 47 M Normoxic 4 7 29 3
13 26 M Normoxic 1 8 34
14 29 F Hypoxic 1 5 38 5
15 20 M Normoxic 4 3 21 3
16 48 F Hypoxic 8 3 34 1
17 22 M Normoxic 1 8 34
18 24 M Hypoxic 1 3 34 5
19 19 M N.A. N.A. N.A. N.A. N.A.
20 31 M Hypoxic 1 5 43 2
21 39 M Normoxic 6 7 26 8
22 25 F Hypoxic 1 3 35 3
23 52 F Normoxic 4 6 43 1
24 36 M Normoxic 4 3 29 3
25 58 M Normoxic 3 7 50 5
26 25 M Normoxic 6 8 17 1
Control 1 42 M Normoxic
Control 2 80 M Normoxic
Control 3 56 M Normoxic
*Mechanism of iInjury: 1, motor vehicle accident; 2, motor bicycle accident;
3, pedal cyclist; 4. pedestrian; 5, penetrating injury; 6, fall/jump; 8, other;
Glasgow Coma Scale (GCS) ≤8: severe; 9–12: moderate; ≥13: minor. ISS, injury
severity score: 0, no injury; 75, maximal untreatable injury; GOSE, extended
Glasgow outcome scale: 1, death; 2, vegetative state; 3, severe disability
(lower band); 4, severe disability (upper band); 5, moderate disability (lower
band); 6, moderate disability (upper band); 7, good recovery (lower band);
8, good recovery (upper band); M, male; F, female. N.A., not available.
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pregnancy, neurodegenerative diseases, HIV and other
chronic infection/inflammatory diseases, or history of
TBI. Clinical parameters were recorded by paramedics
and medical staff, including GCS, hypotension (systolic
blood pressure <90 mmHg) and occurrence of pre-
hospital hypoxia. Patients were allocated to the hypoxic
cohort (SaO2 < 92% or apnoeic or cyanotic at the field of
the accident) or normoxic cohort (normal SaO2) [7].
TBI was classified into focal brain injury or diffuse brain
injury following the Marshall CT score [8] as described
[6]. The injury severity score (ISS) was assessed by in-
cluding extracranial trauma [9]. The extended Glasgow
outcome scale (GOSE) was assessed at 6 months post
admission as described [6]. Control CSF samples were
obtained from hydrocephalus patients undergoing im-
plantation of ventriculo-peritoneal shunts with exclusion
criteria similar to the TBI cohort.
Liquid chromatography-mass spectrometry
(LC-MS) methods
Levels of LPA were measured by high-performance li-
quid chromatography-electrospray ionization-tandem
mass spectrometry as described previously [10]. Briefly,
lipids were extracted from CSF samples using acidified
organic solvents. Sample 10 to 50 mL was combined
with 0.1 M HCL to a final volume of 0.5 mL in an 8-mL
borosilicate glass tube containing 1 mL CHCl3 and 2 mL
MeOH and 50 pmol of 1- hetpadecanoyl 2 hydroxy gly-
cerol 3-phosphate (C17-LPA: Avanti Polar Lipids,
Albaster, AL, USA). The tube was capped, vortexed and
an additional 1 mL of CHCl3 and 1.3 mL 0.1 M HCl
added. The tube was vortexed again and centrifuged (500
× g for 5 minutes) to separate the upper and lower phases.
The lipid containing the lower phase was removed with a
Pasteur pipette to a 4-mL borosilicate glass vial and evap-
orated to dryness under N2 gas using a Zymark Turbovap.
The dried samples were resuspended in 0.1 mL MeOH
and transferred to autosampler vials.
Lipids were analyzed using a Shimadzu UFLC coupled
with an ABI 4000-Qtrap hybrid linear ion trap triple
quadrupole mass spectrometer operated in multiple re-
action monitoring (MRM) mode. Lipids were separated
using an Agilent Zorbax Eclipse XDB C8 column, 5-μm,
4.6 × 150 mm column. The mobile phase consisted of
75/25 of methanol/water with formic acid (0.5%) and
5 mM ammonium formate (0.1%) as solvent A and 99/1
of methanol/water with formic acid (0.5%) and 5 mM
ammonium formate (0.1%) as solvent B. Separation was
achieved using a gradient of 0% B for 1 minute, 0% B to
100% B in the next 1 minute, maintained at 100% B for
the next 10 minutes, and equilibrated to the initial con-
ditions in 3 minutes. The flow rate was 0.5 mL/minute
with a column temperature of 30°C. The sample injec-
tion volume was 10 μL. The mass spectrometer was
operated in negative electrospray ionization mode with
optimal ion source settings determined using a series of
synthetic LPA species. The ion source settings were a
declustering potential of 61 V, entrance potential of
10 V, collision energy of 23 V, collision cell exit potential
of 16 V, curtain gas of 20 psi, ion spray voltage of
5,500 V, ion source gas1/gas2 of 40 psi, and temperature
of 550°C. MRM transitions corresponding to 15 indi-
cated abundant LPA molecular species and the C17
LPA internal standard were monitored. Quantitation
was accomplished by correction for recovery of the
C17 LPA internal standard with reference to calibra-
tion curves generated using authentic LPA standards
(Avanti Polar Lipids) that were quantitated separately
by phosphorous analysis after wet digestion in per-
chloric acid.
Model of controlled cortical contusion in mice
Mice were subjected to CCI as described by Dixon et al.
[11] in rats. Mice were anesthetized for 5 to 10 s with
gaseous isoflurane (1 mL/minute), followed by an intra-
peritoneal injection of ketamine (100 mg/kg, Parnell)/
xylazine (10 mg/kg, Parnell). A sagittal scalp incision
was made to expose the underlying parietal bone and a
2-mm burr hole was drilled using a Dremel 10.8 V drill
with a 0.8 mm tip (Dremel, Europe) into the skull above
the right parietal cortex, 1.5 mm posterior to the Bregma
area and 2.5 mm lateral to the midline. The rounded
section of bone was removed to expose the underlying
cortex. Mice were placed on a stereotaxic frame and a
1.5-mm-deep impact was made into the brain on the ex-
posed cortex using a computer-controlled impactor, with
the center at coordinates anteroposterior = − 2.0, and
mediolateral = + 2.0 from the Bregma area. The follow-
ing parameters were set onto the program linked to the
rounded tip impactor (LinMot-Talk 1100, Spreitenbach
Switzerland): withdrawal of the tip 20 mm away from
resting position at 1 m/s, impact at a velocity of 5 m/s
and depth of 1.5 mm, interval of 100 ms and withdrawal
of the tip 1.5 mm towards the resting position at 1 m/s.
Following the impact, the removed bone section was
placed back onto the skull, with a small amount of par-
affin to close up the brain. The incision was closed up
with a silk 5.0 metric suture (Syneture Tyco Healthcare,
Dublin, Ireland). Mice were given Buprenorphine intra-
peritoneally (0.6 mg/kg, Reckitt Benckiser Healthcare)
and placed on a heat mat for post-surgical recovery.
Sham controls underwent anesthesia, scalp incision and
bone removal, but no injury, and then were sutured,
given analgesic and put on a heat blanket for recovery.
Mouse CSF sampling
CSF sampling from the cisterna magna of the mouse
was carried out in a cohort of mice that had undergone
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TBI. Mice were anesthetised with an intraperitoneal in-
jection of ketamine and xylazine and the head placed in
a stereotaxic frame. After initial skin incision the sub-
cutaneous tissue and muscles (m. biventer cervicis and
m. rectus capitis dorsalis major) were separated by blunt
dissection with forceps and a pair of microretractors was
used to hold the muscles apart. Using a dissecting
microscope the dura mater of the cisterna magna was
punctured by a glass capillary tube and approximately
10 μL of CSF was extracted by capillary action and im-
mediately frozen in liquid nitrogen for analysis.
Behavioral analysis
Neurological function post TBI (at 48 h) was assessed
using DigiGait™ v 11.5 (Mouse Specifics Inc., Quincy,
MA, USA) apparatus as described in [12]. Mice were
run on a transparent treadmill at a speed of 15 cm/s
both before injury and post injury for 5 s. Videos of paw
placement were captured in the ventral plane by the
DigiGait™ software and analyzed by the software. All sur-
gery and behavioral analyses for antibody-treated mice
were performed in a blinded fashion. Gait measurements
were calculated as post to pre-injury ratios of sham ver-
sus trauma mice. All gait parameters for antibody-
treated mice were presented as fold change to trauma
values. Statistical significance was determined by the
Student t-test (unpaired, two-tailed) while comparing
the raw data in each cohort, although the data have been
depicted as fold-change relative to TBI.
Magnetic resonance imaging (MRI)
Mice were intravenously injected with IgG isotype con-
trol (25 mg/kg) or LPA antibody (25 mg/kg) 30 minutes
post TBI, and imaged both 1 day and 7 days after TBI.
MRI scans were performed using a Bruker 4.7 Tesla
small animal MRI scanner (Florey Institute of Neurosci-
ence and Mental Health) to quantify the progression of
tissue damage and the subsequent repair. Mice were ini-
tially anesthetized with approximately 3% isoflurane in a
1:1 mixture of medical-grade air and oxygen. Anesthesia
was maintained throughout scanning with 0.25 to 1.5% iso-
flurane through a nosecone placed over the animal’s snout
and respiration was continuously monitored throughout
the experiment with a pressure-sensitive probe positioned
under the animal’s diaphragm. Anesthetized animals were
laid supine on a purpose-built small-animal holder and
their heads fixed into position with ear and bite bars. A
surface receiver coil was placed over the animals’ heads
and the cradle was inserted into a transmitter coil fixed
inside a BGA12S-HP gradient set for imaging. To ac-
curately assess lesion size, groups of eight mice from
each treatment were used. The MRI protocol consisted of
a 3-plane localizer sequence followed by multi-echo T2
and diffusion-weighted sequences. The total scanning time
was kept to less than 2 h per animal. Multi-echo T2-
weighted images were acquired using a rapid acquisi-
tion, relaxation enhanced (RARE) sequence with RARE
factor = 2; repetition time = 2,500 ms; effective echo
time (TEeff ) = 10, 30, 50, 70, 90 and 110 ms; field of
view (FOV) = 1.6 × 1.6 cm2; matrix = 192 × 192; and 16
slices with thickness = 0.5 mm. The diffusion-weighted
images were acquired with a diffusion-weighted echo-
planar imaging (DWI-EPI) sequence with TR = 7.5 s;
TE = 32.74 ms; repetitions = 3; FOV = 1.6 × 1.6 cm2;
matrix = 64 × 64; 28 slices with thickness = 250 μm; 126
diffusion directions with diffusion gradient duration
(δ) = 3 ms, diffusion gradient separation (Δ) = 14 ms
and b-value = 1,200 s/mm2. Mean diffusivity maps were
derived from the diffusion-weighted data. TBI-affected
regions were manually outlined by a blinded operator
on both T2 weighted and diffusion-weighted images
using ImageJ software (NIH) and volumetric analysis
carried out using Matlab (MathWorks, Natick, MA,
USA).
Histology and brain injury volume analysis
Brains were cut into 10-μm coronal sections starting at
the rostral end, paraffin-embedded and mounted onto
glass slides. Every tenth slide was stained with H&E.
Photomicrographs were captured using a Zeiss Axioskop
microscope and lesion area was determined using the
Image J software (v1.47; NIH). Tissue swelling in the in-
jured side was accounted for by dividing the lesion area
from each section by the ratio of the areas of the injured
relative to uninjuredside. The Cavalieri formula was used
to calculate total lesion volume as follows:
Volume ¼ ΣA t ISF
where A = sum of the corrected lesion areas; t = section
thickness (10 μm) and ISF = inverse of the sampling
fraction (1 in 10 sections was counted, that is, sam-
pling fraction = 1/10). Lesion volume values were ana-
lyzed using the unpaired Student t-test, with a value of
P <0.05 considered statistically significant.
Cytokine measurements
ELISA kits (BD Biosciences, USA) were used to detect
mIL-6 (kit # 555240), mTNF-α (kit # 560478) and mIL-
1β (kit# 559603) levels in brain tissues as per manufac-
turer guidelines: 100 μg protein extract was loaded per
well, with experiments conducted in duplicate. Protein
concentrations of individual samples were determined
using a linear standard curve of IL-6, TNF-α or IL-1β
standards (4–200 pg/mL).
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Antibody-LPA binding measurements
B3 binding to individual LPA species was measured
with the Kinetic Exclusion Assay (KinExA, Sapidyne
Instruments, Boise, ID, USA) using a KinExA 3200
equipped with an autosampler. The LPA conjugate used
to capture the free antibody was prepared by crosslink-
ing 1-(12-mercaptododecanoyl)-2-hydroxy-/sn/-glycero-3-
phosphate to maleimide-activated BSA (Thermo Scientific,
Waltham, MA, USA) in 0.1 M sodium phosphate, 0.15 M
NaCl, pH 7.2. The purified LPA-BSA conjugate was diluted
with running buffer (PBS without calcium and magnesium
(Cellgro, Manassas, VA, USA) with 0.002% azide), absorbed
to PMMA beads (Sapidyne Instruments, Boise, ID, USA)
and blocked with Fraction V fatty acid-free BSA (FAF-BSA,
Calbiochem, USA). The 16:0, 18:0, 18:1, 20:4 acyl LPA spe-
cies (Avanti Polar Lipids) and 18:2 acyl LPA (Echelon
Bioscience, Salt Lake City, UT, USA) were weighed
out in amber glass vials and dissolved in 100% metha-
nol by repeated sonication and vortex mixing as
needed until the solutions were clear. Aliquots (1 to
3 μmol) were transferred to new amber glass vials,
and the methanol was evaporated using a dry argon
stream. The dried LPA aliquots were resuspended in
running buffer containing 1 mg/mL FAF-BSA by re-
peated sonication and vortex mixing to a final LPA
concentration of 0.5 mM.
Samples containing 10 μM of each LPA species
(100 μM 18:0 LPA), 1 nM B3 antibody and 3 μM FAF-
BSA in the KinExA running buffer were prepared in sila-
nized glass tubes. Using a glass syringe, 1 mL of each
sample was transferred to a glass tube containing 2 mL
of a receptor solution (1 nM B3, 3 μM FAF-BSA in run-
ning buffer) and gently mixed. This 3-fold serial dilu-
tion was repeated until 14 sample fractions were
prepared for each LPA species. Sample fractions were
equilibrated for >1 h at room temperature prior to per-
forming equilibrium affinity experiments. B3 captured
on the beads was detected using a DyLight sheep anti-
mouse heavy and light chain secondary (Jackson Immu-
noResearch, West Grove, PA, USA) at 375 ng/mL in
running buffer. Each fraction was analyzed in duplicate
using the KinExA Pro software version 3.6.3 (Sapidyne
Instruments, Boise, ID, USA).
Results
LPA levels are elevated in human and mouse CSF
following TBI
Our previous work showed that LPA receptors were up-
regulated following brain trauma in mice and humans
[3,4]. Although these key components of the LPA signal-
ing pathway were upregulated, the levels of LPA were
not assessed after injury. Consequently, we report here
for the first time, elevated levels of total LPA in human
CSF obtained from patients with TBI compared to non-
injured control individuals (Figure 1A-B). In TBI pa-
tients, levels of LPA in the CSF were substantially and
significantly increased from 0.050 ± 0.007 μM in control
samples to 0.270 ± 0.050 μM in the first 24 h and
returned to basal levels by 120 h (0.059 ± 0.014 μM),
showing that the LPA-pulse usually occurs within the
first 24 h after injury (Figure 1A). Figure 1B depicts the
distribution of LPA isoforms in the human CSF showing
that 16:0 and 18:0 LPA are the predominant isoforms
contributing to the total LPA pulse. These data thus sug-
gest that LPA production and/or degradation in CSF
may be dysregulated/upregulated early in the injury
process.
Before testing the therapeutic value of our anti-LPA
mAbs in a mouse model of TBI, we first sought to cor-
roborate the human findings as to whether LPA levels
were also upregulated in the CSF of injured mice. We
employed the CCI model of TBI as this closely repro-
duces the closed TBI of our patient population [13]. As
shown in Figure 1C, total LPA levels increased in the
CSF of CCI-injured mice 3 h post TBI, returning to
baseline levels at 14 h post injury. A comparison of
Figures 1A versus 1C reinforces the similarity of our
findings between the CCI model and human TBI, as
both displayed dysregulation of LPA in the early hours
post injury. We also performed lipidomics analysis to
determine the isoform distribution of LPA species in
the CSF after injury. Interestingly, Figure 1D shows
that 18:0 LPA is by far the predominant LPA species
contributing to the LPA-pulse produced by the injured
mouse brain.
Anti-LPA mAbs reduce the lesion size following TBI
Having demonstrated the upregulation of the LPA target
in the CCI model (Figure 1C-D), it was important to
demonstrate a causal connection between elevated LPA
levels in the brain and the progression of secondary tis-
sue injury. Accordingly, we assessed the ability of a spe-
cific anti-LPA mAb (B3/Lpathomab), to block the
pathological actions of LPA in CCI mice. We had previ-
ously shown potency of this antibody in blocking LPA
receptor signaling as well as the specificity of this anti-
body towards LPA [5]. We adapted a CCI model origin-
ally described in the rat, which shows a high survival
rate but no chronic neurological impairment [11]. In our
model of CCI, the impactor only travels to 1.5 mm of
depth within the brain, resulting in a mild cortical
lesion.
In our study, mice received B3 or an isotype-matched
control mAb (25 mg/kg) in a double-blinded manner
given intravenously by tail-vein injection 1 h prior or
30 minutes post TBI and were sacrificed 48 h later, for
lesion measurement. As shown in Figure 2, B3 treatment
reduced the hemorrhage normally observed following
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CCI. These data show that compared to isotype control,
B3 significantly reduced the subdural hematoma and the
lesion area (Figure 2A, B respectively). Compared to
controls, brain lesion volume also decreased significantly
by 25.5 ± 2.7% (Figure 2C, n = 6) when mice were treated
with B3 60 minutes prior to injury. Importantly, a single
dose of B3 administered 30 minutes after TBI resulted
in a 36.4 ± 6.4% reduction in lesion volume in B3 treat-
ment compared to control (Figure 2D, n ≥7).
MRI scans were also used to assess lesion size and diffu-
sion characteristics over a temporal profile (Figure 2E-H).
Animals received a single tail-vein administration of B3 or
isotype control 30 minutes after TBI and were then im-
aged by MRI on days 1 and 7. We observed a reduction of
lesion volume in all animals after 7 days when com-
pared to day 1. Importantly, B3 treatment further re-
duced the lesion volume, with a statistically significant
difference observed at 7 days as delineated on the T2
maps and at 1 and 7 days as delineated on the mean
diffusivity maps. The mean diffusivity maps show a sig-
nificance decrease in edema in the B3-treated group at
both day 1 and day 7 compared to mice receiving
isotype-matched mAb control. This finding is mirrored
in the T2 maps with a trend at day 1 and significance
seen at day 7. Together, these data demonstrate that
anti-LPA treatment reduces the lesion size of TBI and
accompanying edema.
Anti-LPA treatment improves behavioral deficits after TBI
The DigiGait system and software were used to assess
changes in neurological function in mice after TBI. We
established that injured mice displayed impairments in
motor functions in their left hind and fore limbs (contra-
lateral limbs to brain injury side) compared to sham
mice in parameters such as stance/swing ratio, % swing
in stride, stance and stride frequency (data not shown).
All gait indices calculated for the B3- and isotype
control-treated mice are presented as fold-change to
TBI. Importantly, the administration of B3, 30 minutes
post TBI significantly improved behavioral outcomes of
the parameters of stance, stride length and stride fre-
quency (Figure 3A-C) and there was a trend to signifi-
cance in step angle, however this was not statistically
significant (Figure 3D). These results indicate that B3
treatment post TBI led to improvements in neurological
function after TBI. This long-term behavioral benefit in
addition to the acute improvements in injured brain vol-
ume seen in Figure 2, suggests that anti-LPA antibodies
have neuroprotective properties in attenuating both the
immediate and secondary phases of brain injury.
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Figure 1 Cerebrospinal fluid (CSF) analysis of lysophosphatidic acid (LPA) content following traumatic brain injury (TBI). Total (A) and
individual (B) LPA levels (means ± standard error of the mean (SEM)) in the CSF of patients with non-penetrating TBI at different time points
(control, n = 3; <24 h, n = 18; >120 hours, n = 11). (F(2,29) = 6.453, P = 0.005 (one-way analysis of variance (ANOVA)); Tukey multiple comparisons
tests: <24 h versus >120 h (Total), **P = 0.007; <24 h versus >120 h (18:0), **P = 0.008; <24 h versus >120 h (20:4), **P = 0.04. Total (C) and individual
(D) LPA levels (means ± SEM) in the CSF of mice post control cortical impact (CCI) at different time points (sham, n = 4; 3 h, n = 6; 14 h, n = 6).
(F(2,13) = 6.674, P = 0.01) by one-way ANOVA; Tukey multiple comparisons test: 3 h versus sham (Total), *P = 0.02 and 3 h versus 14 h (Total), *P = 0.03;
3 h versus sham (18:0), *P = 0.01 and 3 h versus 14 h (18:0), *P = 0.03; 3 h versus sham (18:2), *P = 0.03 and 3 h versus 14 h (18:2), *P = 0.01.
Crack et al. Journal of Neuroinflammation 2014, 11:37 Page 6 of 11
http://www.jneuroinflammation.com/content/11/1/37
Anti-LPA treatment decreases IL-6 after TBI
We assessed whether or not anti-LPA mAb treatment
could have an anti-inflammatory action by examining
the expression levels of key inflammatory cytokine
known to contribute to the secondary phases of neuro-
trauma. For example, IL-6 and IL-1β are important cyto-
kines with levels that correlate with poor outcomes and
behavioral defects, and it has been suggested that pre-
venting IL-6 and IL-1β upregulation could have thera-
peutic benefit in TBI [14]. As expected in our model of
CCI we observed a rapid (4 h) upregulation of IL-6 pro-
tein concentration following TBI, in both hemispheres
(Figure 4). Interestingly, the ELISA data showed a statis-
tically significant decrease in IL-6 protein levels after
treatment with B3 at both 4 and 24 h after TBI when
compared to the isotype control (Figure 4A). Import-
antly, levels of IL-6 observed in the presence of B3 at
both time points were not statistically different from the
levels observed in sham (Figure 4A). However, unlike IL-
6, the levels of IL-1β and TNFα were not altered after
B3 treatment. The dramatic effect of anti-LPA mAb
treatment in reducing IL-6 production suggests that the
structural and functional improvement achieved with
antibody treatment involved LPA-mediated induction of
Figure 2 B3 significantly reduces lesion volume and diffusion following traumatic brain injury (TBI). (A, B) Representative images of
mouse brains 2 days following TBI, isotype control (A) or B3 (B) received 30 minutes post injury, showing extent of hemorrhage. (C, D)
Representative quantification of injury volume 2 days following TBI after Nissl 2 staining, with treatment received 1 hour pre-TBI (C) or 30 minutes
post-TBI (D); means ± standard error of the mean (SEM), n >7 animals; *P <0.05, **P <0.01 by two-tailed t-test. (E) Representative T2 maps of
mouse brain 1 and 7 days following TBI in control animals (isotope) or animals treated with B3 (antibody), both given at 25 mg/kg, 30 minutes
post injury, by tail-vein injection. (F) Representative mean diffusivity map following the same protocol. (G) Quantification of infarct volume using
T2 maps and (H) mean diffusivity maps in isotype controls (TBI) and B3-treated animals (TBI + lysophosphatidic acid (LPA) antibody). Data are
means ± SEM, n = 8 animals; *P <0.05 by t-test.
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IL-6. Moreover, the data corroborate a role of LPA in
enhancing the inflammatory process that follows TBI
and raises the possibility that LPA might modulate the
production of key inflammatory cytokines, such as IL-6,
following neurotrauma.
Discussion
Currently, there are no Food and Drug Administration
(FDA)-approved drugs specifically developed for the
treatment of TBI. The high frequency of morbidity and
mortality in these patients is attributed to the lack of
therapeutic agents that address the mechanisms involved
in brain injury. Here, we provide evidence for a role of
the pro-inflammatory bioactive lipid LPA, in contribut-
ing to TBI neurotrauma by demonstrating the efficacy of
our anti-LPA mAbs to mitigate early effects of injury
such as hemorrhage, edema and injured brain volume as
well as mitigating the longer-term behavioral deficits.
It is likely that the reduced secondary effects mediated
by anti-LPA treatment are due to the ability of the anti-
body to block LPA-induced release of inflammatory cy-
tokines, particularly IL-6. Upregulation of IL-6 in the
brain is considered to be a main driver of the inflam-
matory response after TBI [15] and contributes to the
behavioral deficits, as demonstrated by the ability of
anti-IL-6 antibody treatment to mitigate brain injury
and behavioral responses in the mouse model of TBI
and hypoxia [15]. This is consistent with the association
between elevated serum levels of IL-6 and poor out-
comes in TBI patients [16,17].
Importantly, our study is also the first to demonstrate
that the LPA levels are dysregulated in the CSF as a con-
sequence of brain injury in humans as well as in mice. It
appears that the LPA-pulse occurs in the early, primary
phase of brain injury, as we observed a marked increase
as early as 4 h post injury in the mouse CCI model and
within 24 h in TBI patients. This suggests that LPA may
be one of the first players in response to injury and that
it could contribute to both primary and secondary se-
quelae of events. Presumably, the LPA-pulse was modi-
fied by our anti-LPA mAb treatment such that the
neurotoxic and pro-inflammatory effects of LPA on
brain IL-6 levels were reduced. Both CSF and plasma are
known to contain one of the major enzymes involved in
LPA production, autotaxin, as well as its lysophospholi-
pid substrates [18-20]. The beneficial effects of our anti-
body therapy in reducing hemorrhage and edema can be
explained by the ability of LPA to enhance the perme-
ability of the blood brain barrier (BBB) in vivo [21]. It is
thus possible that the dysregulated LPA observed follow-
ing TBI contributes to an increase permeability of the
BBB, an effect that could thus potentially be blocked by
anti-LPA mAb treatment.
Our most compelling evidence for a causative role of
LPA in murine TBI comes from studies using a specific
murine mAb against LPA, B3. A single intravenous
Figure 3 B3 treatment post TBI significantly improves behavioral outcome. At 48 h after traumatic brain injury (TBI), mice treated with B3
display improvement in the left hind limb parameters of stance (A), stride length (B), stride frequency (C) and step angle (D). B3 and isotype
control values are presented as fold-change to TBI. Data represent mean ± standard error of the mean (SEM), *P <0.05, n = 10 animals per group.
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administration given 30 minutes after injury to CCI mice
was able to significantly and substantially reduce the le-
sion size as assessed both histologically and by T2-
weighted MRI. This neuroimaging technique is employed
routinely in clinical settings to characterize the extent of
brain injury and measure ensuing edema.
The observed near-term neuroprotective effects of the
anti-LPA mAb can be explained by the well-known
effects of LPA in inducing necrosis in cultured neurons,
promoting neurite retraction and preventing neuronal
differentiation and development (reviewed in [2]), effects
that are, in part, reversed by antibody treatment. These
neuroprotective actions seen in the TBI model corrobor-
ate our previous studies showing upregulation of LPA
receptors in the injured mouse spinal cord and human
brain [3,4] and that blocking LPA signaling with B3 im-
proves outcome in mice subjected to SCI [5].
The potent efficacy of the anti-LPA mAb in mitigating
trauma in the murine CCI model, together with the fact
that LPA levels were also dysregulated in the mouse CSF
following TBI, indicate that the findings from this model
may translate well into human TBI therapies and that
our humanized variant of the anti-LPA mAb could be a
novel treatment for the condition. Neutralizing extracel-
lular LPA signaling could be the first therapeutic agent
to mitigate both primary and secondary phases of neuro-
trauma, with resulting potential beneficial outcomes in
rehabilitation and functional recovery for the patients. A
variety of therapeutic interventions in the LPA signaling
pathway could be envisioned and have been discussed
previously [2]. One could develop small molecule inhibi-
tors targeting either the LPA receptors or key enzymes
in the biosynthetic machinery responsible for LPA pro-
duction. Regarding LPA receptor antagonists, there is
the problem that there are six G protein-coupled recep-
tors (GPCRs) for LPA plus two purinergic receptors and
possibly one ion channel (transient receptor potential
cation channel subfamily V member 1 (TRPV1)) This re-
ceptor redundancy may require the development of a
pan-LPA receptor antagonist, as there are several LPA
receptors expressed in the human brain after neuro-
trauma [3]. This would pose a hurdle for medicinal
chemistry. Alternately, one could target the upstream
biosynthetic machinery responsible for LPA upregulation
in the CNS. Although autotaxin (ATX) is a major source
of LPA in the blood and some tissue, it may not be the
source of dysregulated LPA after neurotrauma and fu-
ture work will be needed to determine the role of LPA
production including phospholipase (PLA)1, PLA2, alpha
glycerol kinase (AGK) and other monoacylglycerol
(MAG)-kinases as well as glycerol-3-phosphate acyl-
transferase (GPAT). Lysophosphatidyl choline (LPC), the
substrate for LPA production by ATX, is very low in hu-
man CSF even after TBI (50 nM) and is consistent with
previous reports of low LPC in normal CSF [22], and we
would argue that ATX may not be the key enzyme re-
sponsible for LPA production. However, further experi-
ments are planned to determine the source of the LPA.
It is interesting to note that the LPA profile (Figure 1)
suggests that the brain produces a pattern of LPA spe-
cies quite distinct from plasma. LPA 18:0 is overwhelm-
ingly the predominant species in the injured mouse CSF.
Figure 4 B3 significantly reduces IL-6 production comparable
with sham levels but not IL1-β and TNF-α following traumatic
brain injury (TBI). The graphs show the levels of cytokines in the
ipsilateral hemisphere of mouse brains at 4 and 24 h following TBI.
(A) Il-6. (B) IL-1β (C) TNF-α. Animals received a single intravenous
injection of B3 (25 mg/kg) or its isotype control (Ab isotype), 30
minutes post injury. Data are mean ± standard error of the mean of
triplicates. Statistical significance of B3 treatment was detected by
one way analysis of variance followed by Bonferroni post hoc
analysis, *P <0.05; significance of cytokine levels as a consequence of
TBI injury is indicated by #P <0.05.
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The 18:0 is also a major LPA isoform in the injured hu-
man CSF but 16:0 also appears to be predominant. It is
interesting to note that these species are not the most
abundant in plasma. This needs to be confirmed in more
detailed studies that are planned, but suggests at least,
that hemorrhage (that is, blood source) is not likely the
main source of LPA after TBI. One could further argue
against the blood source of the LPA-pulse in that the
concentration of LPA in CSF (approximately 2 μM for
mouse) is much higher than the 50 to 100 nM levels
typically observed in plasma [23]. One would suspect
that the plasma source of LPA would be diluted even
more when mixed with the CSF. An additional argument
against plasma as the source of the LPA-pulse is the
finding that LPC levels are in the range of 50 nM for
CSF (and do not change after TBI), while LPC levels are
in the 50 to 100 microM range in the plasma [23], indi-
cating that the ratio of LPA/LPC is quite different be-
tween plasma and CSF, including after TBI.
In vitro studies using the Kinetic Exclusion Assay
(KinExA) [24] (Table 2) demonstrate that the anti-LPA
mAbs recognize all relevant LPA species, particularly the
unusual 18:0 and 16:0 LPAs that are abundant in the
CSF of injured mice and humans.
The apparent affinities of the B3 mAb for the various
LPA species are at a minimum of four times higher but
typically two to three orders of magnitude higher than
the affinities enjoyed by the LPA receptors as reported
in the literature, affinities reported to be between ap-
proximately 60 and 800 nM [25,26]. This is a compli-
cated issue as each receptor has different affinities for
the various LPAs, as they are not all equally potent in
activating a particular receptor. Despite this, our anti-
bodies are potent in vitro with regard to binding up all
relevant LPA species. Moreover, one might argue that
the important proof of potency is that our antibodies
demonstrate in vivo efficacy reported here and in miti-
gating SCI [5].
It could be argued that the use of a LPA-neutralizing
antibody could provide an alternate approach to reducing
upregulated LPA signaling. Neutralizing extracellular LPA
with an antibody would silence all of the LPA receptors
and ion channel targets, and would not discriminate on
LPA synthesized by a variety of enzymatic sources, The
disadvantages of antibody therapeutics is the high cost of
the drug product, plus the drug must have access to the
tissue compartment where the target (that is, LPA) is dys-
regulated. Fortunately for antibody therapeutics in the TBI
context, the BBB of the TBI patient is usually permeable
to large proteins like therapeutic antibodies during the
critical-care period where salvaging of damaged nerve tis-
sue would be attempted.
We have recently humanized and affinity-matured the
anti-LPA mAb by grafting the murine CDR regions on
to a human IgGκ1 framework. This preclinical drug can-
didate, LT3114, retains the specificity for key LPA iso-
forms, plus it exhibits high affinity enjoyed by the
murine B3 mAb. The humanized antibody could serve
as a potential therapeutic agent for neurotrauma by lim-
iting the initial injury and, at the same time, reducing
dangerous inflammatory processes, possibly closing
down the permeabilized BBB while stimulating regenera-
tive processes. Thus, neutralizing extracellular LPA with
the humanized mAbs could be the first therapeutic
agent that mitigates both early and late phases of neuro-
trauma with resulting potential beneficial outcomes in
rehabilitation and functional recovery for patients.
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